Abstract
We studied the predictive value of self-reported adherence and plasma drug concentrations on virological rebound to HAART. Among 238 participants in the AdICoNA study who had viral load ≤500 copies/ml, 42 (17.6%) experienced virological rebound by 96 weeks. Both self-reported non-adherence and sub-optimal concentration were independently associated with a higher risk of virological rebound.
| Original language | English |
|---|---|
| Pages (from-to) | 291-296 |
| Number of pages | 6 |
| Journal | Antiviral Therapy |
| Volume | 9 |
| Issue number | 2 |
| Publication status | Published - Apr 2004 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART. / Antinori, Andrea; Cozzi-Lepri, Alessandro; Ammassari, Adriana; Trotta, Maria Paola; Nauwelaers, David; Hoetelmans, Richard; Murri, Rita; Melzi, Sara; Narciso, Pasquale; Nasta, Paola; Zaccarelli, Mauro; Santopadre, Paola; Vecchiet, Jacopo; Izzo, Crescenzo Maria; D'Arminio Monforte, Antonella.
In: Antiviral Therapy, Vol. 9, No. 2, 04.2004, p. 291-296.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Relative prognostic value of self-reported adherence and plasma NNRTI/PI concentrations to predict virological rebound in patients initially responding to HAART
AU - Antinori, Andrea
AU - Cozzi-Lepri, Alessandro
AU - Ammassari, Adriana
AU - Trotta, Maria Paola
AU - Nauwelaers, David
AU - Hoetelmans, Richard
AU - Murri, Rita
AU - Melzi, Sara
AU - Narciso, Pasquale
AU - Nasta, Paola
AU - Zaccarelli, Mauro
AU - Santopadre, Paola
AU - Vecchiet, Jacopo
AU - Izzo, Crescenzo Maria
AU - D'Arminio Monforte, Antonella
PY - 2004/4
Y1 - 2004/4
N2 - We studied the predictive value of self-reported adherence and plasma drug concentrations on virological rebound to HAART. Among 238 participants in the AdICoNA study who had viral load ≤500 copies/ml, 42 (17.6%) experienced virological rebound by 96 weeks. Both self-reported non-adherence and sub-optimal concentration were independently associated with a higher risk of virological rebound.
AB - We studied the predictive value of self-reported adherence and plasma drug concentrations on virological rebound to HAART. Among 238 participants in the AdICoNA study who had viral load ≤500 copies/ml, 42 (17.6%) experienced virological rebound by 96 weeks. Both self-reported non-adherence and sub-optimal concentration were independently associated with a higher risk of virological rebound.
UR - http://www.scopus.com/inward/record.url?scp=2342441340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342441340&partnerID=8YFLogxK
M3 - Article
VL - 9
SP - 291
EP - 296
JO - Antiviral Therapy
JF - Antiviral Therapy
SN - 1359-6535
IS - 2
ER -